Pompe Disease
Pipeline by Development Stage
Drug Modality Breakdown
Rare Diseases is a $21.9B market dominated by a single blockbuster (ELIQUIS), with moderate growth and high consolidation among top-tier pharma players.
Key Trends
- Market concentration: One product (ELIQUIS) represents 83% of market spending
- Complement inhibitors and enzyme replacement therapies gaining momentum
- Active pipeline with 1,790 trials, predominantly Phase 2-3 stage
Career Verdict
Yes, if you seek stability and commercial opportunity with major pharma; proceed cautiously if you want pipeline upside or innovation-driven roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 83% | LAUNCH | Stable | 15.0yr |
| 2 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 5% | LOE_APPROACHING | Declining | |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | PEAK | Stable | 10.2yr |
| 4 | TYVASO DPI (treprostinil) | United Therapeutics | $437M | 2% | PEAK | Stable | 15.7yr |
| 5 | STRENSIQ (asfotase alfa) | AstraZeneca | $259M | 1% | PEAK | Stable |
Drug Class Breakdown
Mature, patent-protected until 2041
Mixed—includes LOE-approaching products
Peak sales, LOE 2036
Stable, long patent protection
Emerging class, no LOE data available
Niche market, specialized patient populations
Career Outlook
StableThe rare disease market is stable but mature, with job growth concentrated in commercial and medical affairs rather than R&D innovation. Consolidation among top pharma (AstraZeneca, BMS, Amgen) limits opportunities for mid-tier companies, but specialist biotech firms show hiring momentum. Patent cliff risk for ELIQUIS (2041) will create restructuring opportunities and potential job flux in downstream years.
Breaking In
Target commercial or quality assurance roles at AstraZeneca, Capricor, or Amgen to build market knowledge; rare disease expertise is portable and valued across therapeutic areas.
For Experienced Professionals
Seek regulatory or medical affairs leadership roles where salary ceiling is highest ($243K-$257K); consider biotech firms like Insmed or Krystal for upside if pipeline approvals accelerate.
In-Demand Skills
Best For
Hiring Landscape
Rare disease hiring is concentrated in commercial roles (75 jobs at $215K avg) and medical affairs (16 jobs at $243K avg), reflecting a mature market's focus on market access and HCP engagement. Top hiring companies include AstraZeneca (38 jobs) and emerging biotech players like Capricor Therapeutics (30 jobs). Department salaries range from $114K-$257K, with regulatory affairs commanding premium compensation.
Top Hiring Companies
By Department
Commercial and regulatory roles offer strong salaries and growth; R&D hiring is minimal (10%), reflecting a consolidation and maturity phase in the market.
On Market (3)
Approved therapies currently available
Competitive Landscape
7 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 20 trials with date data
Clinical Trials (22)
Total enrollment: 2,033 patients across 22 trials
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
Drug-drug Interaction Study
Extension Study for Patients Who Have Participated in a BMN 701 Study
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
Expanded Access for ATB200/AT2221 for the Treatment of IOPD
Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease
A Global Prospective Observational Registry of Patients With Pompe Disease
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
Cognitive and Neurological Pathologies in Pompe Disease
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Response to Diaphragmatic Pacing in Subjects With Pompe Disease
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
Related Jobs in Rare Diseases
Senior Director, Managed Access Programs
Senior TMF Specialist
Associate Director, Omnichannel Enablement
Principal Scientist, Toxicology
Senior Principal Scientist, ADME-PK
Employee Experience Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.